Small Pharma Inc., a neuro-pharmaceutical company focused on psychedelic-assisted therapy, have announced the expansion of its phase I/IIa clinical trial for its lead product, SPL026, a N,N-dimethyltryptamine (“DMT”) based treatment for major depressive disorder (“MDD”).
MAC Clinical Research are proud to have been appointed the trial’s expansion with an additional study site at our Merseyside clinic, bringing the total number of patients in the trial to 42.
Peter Rands, CEO of Small Pharma, said: “MAC’s extensive good clinical practice experience, expertise and infrastructure will provide access to additional sites designed for clinical trials such as ours.
“Working in combination with Hammersmith Medicines Research, we can dose more patients and accelerate our timelines to deliver proof of concept of our lead product, SPL026, through this Phase I/IIa clinical trial.”
We are excited to be collaborating with Small Pharma on their safety and efficacy of DMT-based therapy in patients with moderate/severe MDD at our bespoke Liverpool research facilities for psychedelic research,” said Dr. Mark Dale, CEO, and principal investigator, Dr. Paul Westhead. “In addition, we are looking forward to being a part of developing DMT and deuterium-enriched tryptamines in combination with psychotherapy as a potential rapid onset, sustained treatment for mental health disorders”.
Psychedelics have been shown to have therapeutic benefits in disorders such as depression, substance abuse and post-traumatic stress disorder. Clinical research suggests that DMT will break or disrupt the neuronal pathways that underlie these negative thought processes and by doing so, may facilitate the benefits of therapy given in combination with DMT. Follow MAC on social media or register your interest in future trials to stay up to date with this upcoming study.
